Cancerous B cell treatment using substituted nucleoside derivati

Details Cancerous B cell treatment using substituted nucleoside derivati Cancerous B cell treatment using substituted nucleoside derivati

1993-11-12

1995-12-19

Kim, Kay K. A.

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

514 45, 514908, 4352402, A61K 3939, A61K 3170, C12N 506, C12N 508

Patent

active

054766591

ABSTRACT:
Processes for the killing of cancerous B cells, and particularly chronic lymphocytic leukemia (CLL) cells are disclosed. In one process, cancerous B cells that do not proliferate when contacted with an immune response-enhancing agent are contacted with an amount of such an agent sufficient to cause peripheral CLL cells to undergo blast transformation and proliferation. The contacted cells are then maintained for a time period sufficient for them to die from that contact. Further contacting of those cells with a cytotoxic amount of an anti-cancer drug or cytotoxic conjugate enhances the death of those cancer cells. In another process, peripheral CLL cells that proliferate on contact with an immune response-enhancing-agent are contacted with a proliferation-inducing amount of such an agent. The contacted cells are maintained for a time period sufficient to undergo blast transformation and proliferation, and the blasts are then contacted with a cytotoxic amount of an anti-cancer drug or cytotoxic conjugate and maintained.

REFERENCES:
patent: 4539205 (1985-09-01), Goodman et al.
patent: 4596676 (1986-06-01), Cullinan
patent: 4643992 (1987-02-01), Goodman et al.
patent: 4724213 (1988-02-01), Epstein
patent: 4746651 (1988-05-01), Goodman
patent: 4801688 (1989-01-01), Laguzza et al.
patent: 4814438 (1989-03-01), Armour et al.
patent: 4861579 (1989-08-01), Meyer, Jr. et al.
patent: 4948730 (1990-08-01), Goodman et al.
patent: 5166141 (1992-11-01), Goodman et al.
patent: 5317013 (1994-05-01), Goodman et al.
Goodman et al., (1991) Blood 78(suppl. 1)=437(a) Abstr. No. 1738.

Affiliated with

Also associated with

Rating

Cancerous B cell treatment using substituted nucleoside derivati does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancerous B cell treatment using substituted nucleoside derivati, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancerous B cell treatment using substituted nucleoside derivati will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-990695